NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
Neonc Technologies, Inc.
Hoosier Cancer Research Network
AstraZeneca
University of Kentucky
Incyte Corporation
The Third Affiliated hospital of Zhejiang Chinese Medical University
Fundación GECP